A Phase 3 interventional study of Capecitabine and Cisplatin in Gastric Cancer, sponsored by Hoffmann-La Roche. Terminated at 117 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies testing capecitabine in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Capecitabine · Stomach Neoplasms.
Among the 100 studies testing capecitabine in Stomach Neoplasms, this one is the 14th largest by enrollment of the 97 interventional ones that give a count, is one of 7 that started in 2011, is one of 17 in phase 3, and was the 59th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →9 of the 100 studies testing capecitabine in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Jinbo Yue · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
Henry Ford Health System · Sites in United States
Ages 18+
RemeGen Co., Ltd. · Sites in China
Ages 18+
Hallym University Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 19 · Phase 4 2
First in 1999; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 296 is above the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 50 across the 97 interventional studies. Of the 66 that completed or were terminated, 21 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 100 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
29 studies in Stomach Neoplasms by Hoffmann-La Roche: none open now, 2 under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 8th registered.
Hoffmann-La Roche’s Stomach Neoplasms studies by the year they started, since 2003.
3 of the studies testing capecitabine in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT06748508Fudan UniversityComparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer | 2027-07-25 |
| NCT07069712AstraZenecaA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | 2027-11-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 100 studies testing capecitabine in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 29 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with HER2-positive metastatic gastric or gastro-esophageal junction adenocarcinoma. Participants who have not received prior treatment for metastatic disease will be randomized to receive Herceptin intravenously as either an 8-milligram per kilogram (mg/kg) loading dose followed by 6 mg/kg every 3 weeks (q3w) as standard of care or an 8-mg/kg loading dose followed by 10 mg/kg q3w until disease progression. Capecitabine will be administered for 6 cycles at a dose of 800 milligrams per meter-squared (mg/m\^2) orally twice a day on Days 1 to 14 of each 3-week cycle, and cisplatin will be administered intravenously for 6 cycles at a dose of 80 mg/m\^2 on Day 1 of each 3-week cycle. Herceptin will be continued until disease progression occurs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m\^2 intravenously q3w plus capecitabine 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
Drug: Capecitabine · Drug: Cisplatin · Drug: Herceptin
Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m\^2 intravenously q3w plus capecitabine 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
Drug: Capecitabine · Drug: Cisplatin · Drug: Herceptin
Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Also known as: Trastuzumab
Percentage of Participants Who Died - FAS
The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the FAS with available data.
Time frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Overall Survival - FAS
Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the FAS using the Kaplan-Meier approach. The 95 percent (%) confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.
Time frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Percentage of Participants Who Died - Per Protocol Set (PPS)
The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.
Time frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Overall Survival - PPS
Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the PPS using the Kaplan-Meier approach. The 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Percentage of Participants With Disease Progression or Death - PPS
Disease progression was defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of ≥5 millimeters (mm). The percentage of participants who died or experienced disease progression as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.
Time frame: From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)
Progression-Free Survival - PPS
Progression-free survival was defined as the time between the day of randomization and the date of first documentation of disease progression or date of death, whichever occurred first, measured following RECIST Version 1.1 criteria. Disease progression was defined as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of ≥5 mm. The 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)
Percentage of Participants With Objective Response - PPS
Objective response was defined as the occurrence of either a complete response (CR) or partial response (PR) as determined by RECIST Version 1.1 based on investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have reduction in short axis to \<10 mm. PR was defined as a ≥30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. The 95% CI was constructed using Blyth-Still-Casella method.
Time frame: From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)
Trastuzumab Cmin on Day 21 of Cycles 1 to 11 - FAS
Cmin samples were obtained in all participants randomized to receive Herceptin (FAS). The observed Cmin was recorded, averaged among all participants, and expressed in μg/mL.
Time frame: Day 21 of Cycle 1, 2, 3, 4, 5, 7, 9, 11 (cycle length = 21 days)
Trastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS
Trastuzumab serum concentration samples were obtained in all participants randomized to receive Herceptin (FAS). The observed concentration values were recorded, averaged among all participants, and expressed in μg/mL.
Time frame: Pre-dose (0 minutes) and within 15 minutes after end of 2-hour Herceptin infusion on Day 1 of Cycle 1 (cycle length = 21 days)
| Milestone | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| Started | 148 | 148 |
| Treated (safety population) | 147 | 147 |
| Completed | 0 | 0 |
| Not completed | 148 | 148 |
| Withdrew: Never treated | 1 | 1 |
| Withdrew: Death | 77 | 84 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Non-compliance | 1 | 0 |
| Withdrew: Withdrawal by subject | 13 | 2 |
| Withdrew: Study terminated by sponsor | 53 | 58 |
The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the FAS with available data.
| percentage of participants | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| Percentage of Participants Who Died - FAS | 46.8 | 54.0 |
Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the FAS using the Kaplan-Meier approach. The 95 percent (%) confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.
| months | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| Overall Survival - FAS | 12.485 (10.086 to 13.864) | 10.612 (9.363 to 12.419) |
The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.
| percentage of participants | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| Percentage of Participants Who Died - Per Protocol Set (PPS) | 51.5 | 59.4 |
Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the PPS using the Kaplan-Meier approach. The 95% CI for median was computed using the method of Brookmeyer and Crowley.
| months | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| Overall Survival - PPS | 10.809 (8.082 to 14.752) | 9.363 (5.552 to 14.357) |
Disease progression was defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of ≥5 millimeters (mm). The percentage of participants who died or experienced disease progression as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.
| percentage of participants | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| Percentage of Participants With Disease Progression or Death - PPS | 75.8 | 81.3 |
Progression-free survival was defined as the time between the day of randomization and the date of first documentation of disease progression or date of death, whichever occurred first, measured following RECIST Version 1.1 criteria. Disease progression was defined as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of ≥5 mm. The 95% CI for median was computed using the method of Brookmeyer and Crowley.
| months | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| Progression-Free Survival - PPS | 5.388 (2.793 to 7.721) | 4.370 (2.727 to 6.834) |
Objective response was defined as the occurrence of either a complete response (CR) or partial response (PR) as determined by RECIST Version 1.1 based on investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have reduction in short axis to \<10 mm. PR was defined as a ≥30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. The 95% CI was constructed using Blyth-Still-Casella method.
| percentage of participants | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| Percentage of Participants With Objective Response - PPS | 57.6 (40.12 to 73.16) | 50.0 (31.89 to 68.11) |
Cmin samples were obtained in all participants randomized to receive Herceptin (FAS). The observed Cmin was recorded, averaged among all participants, and expressed in μg/mL.
| μg/mL | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| Cycle 1 (n=100,99) | 17.1 ± 14.3 | 18.1 ± 18.1 |
| Cycle 2 (n=93,76) | 19.2 ± 8.8 | 35.3 ± 19.4 |
| Cycle 3 (n=77,71) | 23.2 ± 11.8 | 40.7 ± 20.6 |
| Cycle 4 (n=73,61) | 25.9 ± 12.1 | 47.6 ± 20.2 |
| Cycle 5 (n=70,60) | 26.7 ± 10.6 | 49.3 ± 23.2 |
| Cycle 7 (n=51,44) | 31.4 ± 14.2 | 58.1 ± 27.6 |
| Cycle 9 (n=31,24) | 33.7 ± 17.6 | 61.0 ± 23.9 |
| Cycle 11 (n=24,16) | 32.5 ± 14.7 | 68.4 ± 35.9 |
Trastuzumab serum concentration samples were obtained in all participants randomized to receive Herceptin (FAS). The observed concentration values were recorded, averaged among all participants, and expressed in μg/mL.
| μg/mL | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| Pre-dose (n=109,110) | 0.168 ± 1.69 | 0.0204 ± 0.123 |
| End of infusion (n=110,111) | 126 ± 59.6 | 137 ± 55.7 |
Collected over From date of randomization until 6 months after last dose of study drug or end of study (up to approximately 32 months or final data collection date of 25 August 2015). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine + Cisplatin + Herceptin (6 mg/kg) | — | 35/147 (23.8%) | 123/147 (83.7%) |
| Capecitabine + Cisplatin + Herceptin (10 mg/kg) | — | 38/147 (25.9%) | 122/147 (83%) |
| Event | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 7/147 | 6/147 |
| VomitingGastrointestinal disorders | 5/147 | 3/147 |
| DiarrhoeaGastrointestinal disorders | 0/147 | 4/147 |
| Acute kidney injuryRenal and urinary disorders | 4/147 | 2/147 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/147 | 3/147 |
| Renal failureRenal and urinary disorders | 3/147 | 0/147 |
| Gastric haemorrhageGastrointestinal disorders | 2/147 | 0/147 |
| NauseaGastrointestinal disorders | 2/147 | 0/147 |
| Obstruction gastricGastrointestinal disorders | 2/147 | 1/147 |
| PneumoniaInfections and infestations | 2/147 | 2/147 |
| Event | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 61/147 | 69/147 |
| NauseaGastrointestinal disorders | 55/147 | 55/147 |
| AnaemiaBlood and lymphatic system disorders | 47/147 | 40/147 |
| VomitingGastrointestinal disorders | 36/147 | 42/147 |
| Decreased appetiteMetabolism and nutrition disorders | 32/147 | 27/147 |
| DiarrhoeaGastrointestinal disorders | 24/147 | 30/147 |
| LeukopeniaBlood and lymphatic system disorders | 26/147 | 24/147 |
| ConstipationGastrointestinal disorders | 19/147 | 25/147 |
| FatigueGeneral disorders | 25/147 | 23/147 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 14/147 | 20/147 |
The Full Analysis Set (FAS) population included all participants who were randomized in this study.
| Age, Continuous(years) | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) | Total |
|---|---|---|---|
| Mean | 59.5 ± 10.6 | 62.4 ± 10.7 | 60.0 ± 10.7 |
| Sex: Female, Male(Participants) | Capecitabine + Cisplatin + Herceptin (6 mg/kg) | Capecitabine + Cisplatin + Herceptin (10 mg/kg) | Total |
|---|---|---|---|
| Female | 32 | 37 | 69 |
| Male | 116 | 111 | 227 |
Showing the first 100 of 117 sites across 25 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2011, a primary completion of Feb 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Capecitabine · Cisplatin · Trastuzumab